Clinical trial
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During…
NCT01012492 · Boston Children's Hospital, Other · Completed
Key facts
| NCT number | NCT01012492 |
|---|---|
| Title | Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT |
| Official title | Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant |
| Lead sponsor | Boston Children's Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts) and 3 more |
| Intervention type | Drug |
| Interventions | Abatacept |
| Enrollment | 11 |
| Start date | Nov 1, 2009 |
| Primary completion | Nov 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Nov 13, 2009 |
| Last update posted | Nov 21, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: